Posts
Applications are invited for a fully funded 3.5 years PhD CDT DT4Health studentship (including tuition fees, annual stipend and consumables) starting in October 2025.
![PhD opportunity [October 2025 start] on "Patient-specific CTA-informed in-silico simulation of interventional fluoroscopy: A digital twin for stroke patients"](/post/2024-11-18-fluoroscopydt-phd/featured_hu14137464882786301806.webp)
Applications are invited for a fully funded 3.5 years PhD CDT DT4Health studentship (including tuition fees, annual stipend and consumables) starting in October 2025.
![PhD opportunity [October 2025 start] on "Machine Learning Tool for Predicting Digital Twin Trajectories of Meningioma Growth on MRI Brain Scans"](/post/2024-11-18-meningiomagrowth-phd/featured_hu1085588802724171219.webp)
Applications are invited for the fully funded 1+3 years MRes+PhD or 4 years PhD MRC DTP studentship (including home tuition fees, annual stipend and consumables) starting in October 2025.
![PhD opportunity [October 2025 start] on "Computational stereovision synthesis from monocular neuroendoscopy"](/post/2024-09-24-monostereo-phd/featured_hu1135287484882195314.webp)
Tom Vercauteren has been appointed as Senior Editor for the highly-ranked Medical Image Analysis journal, an official journal of the MICCAI society. Sebastien Ourselin also features on the editorial board of the publication.
![PhD opportunity [October 2024 start] on "Text promptable semantic segmentation of volumetric neuroimaging data"](/post/2023-10-04-textpromptseg-phd/featured_hu6165512449039781614.webp)
On 21st September we held our fourth ‘Science for Tomorrow’s Neurosurgery’ PPI group meeting online, with presentations from Oscar, Matt and Silvère. Presentations focused on an update from the NeuroHSI trial, with clear demonstration of improvements in resolution of the HSI images we are now able to acquire; this prompted real praise from our patient representatives, which is extremely reassuring for the trial going forward. We also took this opportunity to announce the completion of the first phase of NeuroPPEYE, in which we aim to use HSI to quantify tumour fluorescence beyond that which the human eye can see. Discussions were centered around the theme of “what is an acceptable number of participants for proof of concept studies,” generating very interesting points of view that ultimately concluded that there was no “hard number” from the patient perspective, as long as a thorough assessment of the technology had been carried out. This is extremely helpful in how we progress with the trials, particularly NeuroPPEYE, which will begin recruitment for its second phase shortly. Once again, the themes and discussions were summarized in picture format by our phenomenal illustrator, Jenny Leonard (see below) and we are already making plans for our next meeting in February 2024!
